SGLT2 inhibitors are a type of diabetes medication that is currently generating excitement for their potential to help obese individuals lose weight. In a recent study, researchers found that the SGLT2 inhibitor canagliflozin can reduce the accumulation of senescent cells in obese mice on a high-fat diet. The drug helps immune cells clear out these senescent cells more efficiently.
Being overweight, particularly with excess visceral fat, accelerates the buildup of senescent cells in the body. These cells play a role in the negative effects of obesity and aging. While there is interest in using SGLT2 inhibitors to slow aging, it’s important to consider further research, especially in normal-weight subjects, to understand the full potential of these drugs.
The study showed that SGLT2 inhibition can eliminate senescent cells and improve age-related health issues. This effect was seen in obese mice, where treatment with canagliflozin reduced senescence in adipose tissue and improved metabolic function. The drug even extended lifespan in mice with premature aging.
Research has shown that eliminating senescent cells can improve age-related health problems. In this study, blocking SGLT2 enhanced senescent cell clearance, leading to better aging outcomes.
Canagliflozin treatment increased levels of AICAR, a metabolite that boosts immune cell activity against senescent cells. This indirect senolytic effect suggests that SGLT2 inhibition could have promising anti-aging benefits.
